NextPlat (NXPL) EBITDA Margin Growth (1y) (2016 - 2026)
Powered by 
Analysis
NextPlat (NXPL) EBITDA Margin Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | -1,647.00 |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | -634.00 |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -1,576.00 |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 93.00 |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 840.00 |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 864.00 |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -12,485.00 |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | -258.00 |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 3,802.00 |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 1,275.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,275.00 |
| Mar 31, 2026 | 377.00 |
| Dec 31, 2025 | -1,478.00 |
| Sep 30, 2025 | 3,759.00 |
| Jun 30, 2025 | 5,032.00 |
| Mar 31, 2025 | -443.00 |
| Dec 31, 2024 | 7,703.00 |
| Sep 30, 2024 | -2,931.00 |
| Jun 30, 2024 | 4,932.00 |
| Mar 31, 2024 | 3,252.00 |
| Dec 31, 2023 | 1,041.00 |
| Sep 30, 2023 | 5,955.00 |
| Jun 30, 2023 | -6,006.00 |
| Mar 31, 2023 | -1,972.00 |
| Dec 31, 2022 | 6,919.00 |
| Sep 30, 2022 | 1,711.00 |
| Jun 30, 2022 | -2,531.00 |
| Mar 31, 2022 | -287.00 |
| Dec 31, 2021 | -9,346.00 |
| Sep 30, 2021 | -6,725.00 |